Shares of global pharmaceutical company Eli Lilly (NYSE: LLY ) jumped 3.4% in the morning session after the company announced very positive results of the Phase 3 trial for its next-generation weight loss candidate, retatrutide.
The triple agonist drug, which activates three hormone receptors (GIP, GLP-1, and glucagon), met all key primary and secondary endpoints in patients with obesity and knee osteoarthritis. Key data showed that the highest dose of retatrutide led to an average weight loss of up to $28.7% over 68 weeks, a result that significantly exceeded the efficacy of its existing blockbuster, Zepbound.
In addition, the trial showed substantial improvements in pain and physical function. Investors viewed the successful trial as strong validation of the dominance of Lilly’s growing pipeline in the massive and rapidly expanding cardiometabolic health market, bolstering the stock’s premium valuation.
After the initial pop the shares cooled to $1,015, up 2.3% from the previous close.
Now is the time to buy Eli Lilly? Access our full analysis report here.
Eli Lilly shares are somewhat volatile and have had 10 moves greater than 5% over the past year. In that context, today’s move indicates that the market considers this news significant but not something that fundamentally changes its perception of the business.
The biggest move we wrote about over the last year was 8 months ago when the stock gained 15.3% on news that results from a Phase 3 trial showed that its experimental drug, Orforglipron, performed significantly well in helping patients manage obesity and diabetes. The stock’s reaction suggested investors were optimistic that, if approved, Lilly could scale production quickly and tap the fast-growing diabetes and obesity markets.
Eli Lilly is up 30.4% year-to-date, and at $1,015 per share, is trading near its 52-week high of $1,110 from November 2025. Investors who bought $1,000 of Eli Lilly stock 5 years ago would now be looking at an investment worth $6,339.
The 1999 book Gorilla Game predicted that Microsoft and Apple would dominate technology before it happened. Her thesis? Identify platform winners early. Today, enterprise software companies that integrate generative AI are becoming the new gorillas. Click here for access to our special report that reveals one profitable leader already riding this wave.